ALZN net incomeQ1 2027-$3.03M
ALZN net income was -$3.03M in fiscal Q1 2027 (ended Jul 31, 2026), compared with -$2.70M a year earlier. For the full fiscal 2026 it was -$8.77M, compared with -$4.51M in fiscal 2025.
Alzamend Neuro Inc. (ALZN) financials
For the twelve months ended Jul 31, 2026, Alzamend Neuro Inc. reported -$9.10M of net income.
- Net income, TTM
- -$9.10M
- Cash
- $7.59M
- Market cap
- $6.9M
FY2020FY2026
ALZN revenue and earnings growth
ALZN EPSQ1 2027-$0.68
ALZN diluted EPS was -$0.68 in fiscal Q1 2027 (ended Jul 31, 2026). For the full fiscal 2026 it was -$2.63.
Income statement
| Line item | Apr 30, 2026 | Apr 30, 2025 | Apr 30, 2024 | Apr 30, 2023 | Apr 30, 2022 | Apr 30, 2021 | Apr 30, 2020 |
|---|---|---|---|---|---|---|---|
| Research and development | $3.63M | $1.41M | $6.46M | $7.45M | $5.20M | $1.31M | $1.07M |
| Selling, general and admin | $5.14M | $3.08M | $3.48M | $7.42M | $7.12M | $3.64M | $3.35M |
| Operating income | -$8.77M | -$4.50M | -$9.94M | -$14.87M | -$12.32M | -$4.95M | -$4.42M |
| Interest expense | $6.6K | $18.0K | $10.1K | $7.7K | $46.5K | $142.4K | - |
| Pre-tax income | -$8.77M | -$4.51M | -$9.95M | -$14.88M | -$12.36M | -$5.05M | -$4.41M |
| Net income | -$8.77M | -$4.51M | -$9.95M | -$14.88M | -$12.36M | -$5.05M | -$4.41M |
| EPS, basic | -$2.63 | -$11.32 | -$1190.97 | -$2060.10 | -$12.60 | -$6.30 | -$5.40 |
| EPS, diluted | -$2.63 | -$11.32 | -$1190.97 | -$2060.10 | -$12.60 | -$6.30 | -$5.40 |
| Diluted shares | 3.3M | 450,799 | 8,241.556 | 7,223.622 | 989,947.489 | 807,223.033 | 791,706.444 |
Balance sheet
| Line item | Apr 30, 2026 | Apr 30, 2025 | Apr 30, 2024 | Apr 30, 2023 | Apr 30, 2022 | Apr 30, 2021 | Apr 30, 2020 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | $710.7K | $3.95M | $376.0K | $5.14M | $14.06M | $1.93M | $90.3K |
| Current assets | $1.76M | $4.18M | $455.2K | $5.84M | $14.41M | $2.91M | $1.81M |
| Total assets | $2.08M | $4.60M | $631.6K | $5.92M | $14.52M | $2.91M | $1.81M |
| Current liabilities | - | - | - | $2.87M | $1.16M | $899.6K | $992.3K |
| Total liabilities | $1.35M | $634.8K | $3.23M | $2.87M | $1.16M | $899.6K | - |
| Shareholders' equity | $733.2K | $3.97M | -$2.59M | $3.05M | $13.35M | $2.01M | $821.7K |
Cash flow
| Line item | Apr 30, 2026 | Apr 30, 2025 | Apr 30, 2024 | Apr 30, 2023 | Apr 30, 2022 | Apr 30, 2021 | Apr 30, 2020 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$8.07M | -$6.57M | -$8.27M | -$8.92M | -$6.61M | -$2.71M | -$2.35M |
| Investing cash flow | - | -$300.0K | -$147.2K | - | -$106.5K | $100.9K | $105.0K |
| Financing cash flow | $4.83M | $10.44M | $3.65M | $200 | $18.85M | $4.45M | $2.29M |
| Stock-based compensation | $707.5K | $325.1K | $955.6K | $3.58M | $4.41M | $2.03M | $1.80M |
Key ratios
| Line item | Apr 30, 2026 | Apr 30, 2025 | Apr 30, 2024 | Apr 30, 2023 | Apr 30, 2022 | Apr 30, 2021 | Apr 30, 2020 |
|---|---|---|---|---|---|---|---|
| Return on equity | -1196.4% | -113.8% | - | -488.5% | -92.6% | -250.7% | -536.7% |
| Return on assets | -421.9% | -98.1% | -1575.0% | -251.5% | -85.2% | -173.3% | -243.1% |
| Current ratio | - | - | - | 2.03 | 12.37 | 3.24 | 1.83 |
Income statement
| Line item | Jul 31, 2026 | Apr 30, 2026 | Jan 31, 2026 | Oct 31, 2025 | Jul 31, 2025 | Apr 30, 2025 | Jan 31, 2025 | Oct 31, 2024 | Jul 31, 2024 | Apr 30, 2024 | Jan 31, 2024 | Oct 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $1.09M | $434.0K | $1.28M | $176.3K | $1.74M | $450.2K | $447.1K | $311.1K | $206.6K | $183.4K | $1.91M | $2.00M |
| Selling, general and admin | $1.94M | $2.44M | $919.0K | $821.8K | $959.3K | $688.8K | $590.3K | $1.05M | $755.8K | $666.6K | $751.2K | $904.9K |
| Operating income | -$3.03M | -$2.87M | -$2.20M | -$998.1K | -$2.70M | -$1.14M | -$1.04M | -$1.36M | -$962.4K | -$850.1K | -$2.66M | -$2.90M |
| Interest expense | $2.0K | $150 | $1.3K | $2.6K | $2.5K | $509 | $2.0K | $3.5K | $12.0K | $1.5K | $2.5K | $4.3K |
| Net income | -$3.03M | -$2.87M | -$2.20M | -$1.00M | -$2.70M | -$1.14M | -$1.04M | -$1.36M | -$974.4K | -$851.5K | -$2.66M | -$2.91M |
| EPS, basic | -$0.68 | - | -$0.58 | -$0.30 | -$1.28 | - | -$1.75 | -$3.61 | -$102.78 | - | -$33.93 | -$39.87 |
| EPS, diluted | -$0.68 | - | -$0.58 | -$0.30 | -$1.28 | - | -$1.75 | -$3.61 | -$102.78 | - | -$33.93 | -$39.87 |
| Diluted shares | 4.5M | - | 3.8M | 3.4M | 2.1M | - | 611,978 | 392,411 | 9,479.333 | - | 78,381.333 | 72,930.889 |
Balance sheet
| Line item | Jul 31, 2026 | Apr 30, 2026 | Jan 31, 2026 | Oct 31, 2025 | Jul 31, 2025 | Apr 30, 2025 | Jan 31, 2025 | Oct 31, 2024 | Jul 31, 2024 | Apr 30, 2024 | Jan 31, 2024 | Oct 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $7.59M | $710.7K | $2.71M | $4.45M | $5.62M | $3.95M | $3.36M | $4.09M | $1.19M | $376.0K | $282.9K | $200.1K |
| Current assets | $8.25M | $1.76M | $3.70M | $4.72M | $5.93M | $4.18M | $3.95M | $4.77M | $1.42M | $455.2K | $593.6K | $781.9K |
| Total assets | $8.54M | $2.08M | $4.04M | $5.09M | $6.33M | $4.60M | $4.18M | $5.01M | $1.67M | $631.6K | $782.6K | $983.6K |
| Current liabilities | - | - | - | - | - | - | - | - | - | - | $3.83M | - |
| Total liabilities | $2.74M | $1.35M | $1.86M | $717.5K | $983.3K | $634.8K | $725.9K | $1.25M | $2.88M | $3.23M | $4.57M | $3.67M |
| Shareholders' equity | $5.80M | $733.2K | $2.20M | $4.37M | $5.34M | $3.97M | $3.45M | $3.75M | -$1.21M | -$2.59M | -$4.26M | -$2.68M |
Cash flow
| Line item | Jul 31, 2026 | Apr 30, 2026 | Jan 31, 2026 | Oct 31, 2025 | Jul 31, 2025 | Apr 30, 2025 | Jan 31, 2025 | Oct 31, 2024 | Jul 31, 2024 | Apr 30, 2024 | Jan 31, 2024 | Oct 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$1.14M | -$2.80M | -$1.74M | -$1.17M | -$2.36M | -$688.7K | -$1.42M | -$3.40M | -$1.06M | -$1.43M | -$2.03M | -$1.51M |
| Investing cash flow | - | - | - | - | - | -$210.0K | $0 | $0 | -$90.0K | $0 | $0 | $0 |
| Financing cash flow | $8.02M | $794.8K | $0 | $0 | $4.04M | $1.49M | $688.7K | $6.30M | $1.96M | $1.52M | $2.11M | - |
| Stock-based compensation | $77.2K | $623.8K | $9.3K | $31.5K | $42.9K | $81.3K | $81.3K | $81.3K | $81.3K | $81.3K | $186.6K | $318.3K |
Key ratios
Source: XBRL data Alzamend Neuro Inc. files with the SEC, latest filing dated Sep 10, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures and share counts are restated for stock splits the filings show: 1-for-10, first reported Dec 11, 2024; 1-for-9, first reported Dec 9, 2025.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
ALZN peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| ALZN | - | - | -$9.10M | - | $6.9M |
| AVXL | - | - | -$13.02M | - | $113.1M |
| ANVS | $0 | - | -$49.52M | - | $38.6M |
| CGTX | - | - | -$15.99M | - | $65.3M |
| PRTA | $52.73M | +347.4% | -$23.96M | -45.4% | $450.9M |
| ABOS | - | - | -$103.96M | - | $17.6M |
ALZN FAQ
4 questionsIs ALZN profitable?
No. Alzamend Neuro Inc. reported a net loss of $9.10M for the twelve months ended Jul 31, 2026.How much cash and debt does ALZN have?
Alzamend Neuro Inc. reported $7.59M in cash and cash equivalents on its most recent balance sheet in SEC filings.When did ALZN last report financial results?
The latest statements here come from Alzamend Neuro Inc.'s 10-Q filed on Sep 10, 2026, covering the period ended Jul 31, 2026.Where does this ALZN financial data come from?
Quantisnow builds these statements from the structured XBRL data Alzamend Neuro Inc. files with the SEC. It is provided for information only and is not investment advice.